NOVARTIS

TAF MEK melanoma - Management of patients with BRAF-positive melanoma - HCP

Prescribing information

Image

Image

Management of patients with *BRAF*-positive melanoma

TAFINLAR® (dabrafenib) in combination with MEKINIST® (trametinib) is indicated in adult patients with unresectable or metastatic melanoma with a *BRAF* V600 mutation.[1,2]

TAFINLAR in combination with MEKINIST is indicated for the adjuvant treatment of adult patients with Stage III melanoma with a *BRAF* V600 mutation, following complete resection.[1,2]

For the full safety profile, please refer to the Summary of Product Characteristics (SmPC) for TAFINLAR and MEKINIST.

Adverse event reporting: Details of how to report adverse events are available at the bottom of the page. Please refer to the respective SmPC for all licensed indications.

Helping patients on their TAFINLAR + MEKINIST treatment journey

TAFINLAR + MEKINIST offers oral dosing. TAFINLAR is taken twice daily, whilst MEKINIST is taken once a day, with the morning or evening dose of TAFINLAR[1,2]

TAFINLAR + MEKINIST offers oral dosing. It is the only oral option in the adjuvant setting and offers a low pill burden to patients in the metastatic setting.[1–4] Dosing is the same for both adjuvant and metastatic treatment settings.[1,2]

Please select an option below to learn more about dosing and administration, and how to manage adverse events with dose modifications.

BRAF V600, mutation of the *BRAF* gene at valine (V) 600; SmPC, summary of product characteristics.

References

1. TAFINLAR (dabrafenib) Summary of Product Characteristics.
2. MEKINIST (trametinib) Summary of Product Characteristics.
3. BRAFTOVI (encorafenib) Summary of Product Characteristics.
4. MEKTOVI (binimetinib) Summary of Product Characteristics.

TAFINLAR + MEKINIST dosing and administration

Show more

TAFINLAR + MEKINIST dose modifications

Show more

UK | April 2025 | FA-11392338

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis online through the pharmacovigilance intake (PVI) tool at www.novartis.com/report, or alternatively email medinfo.uk@novartis.com or call 01276 698370.
